TraMetinib - CAS# 871700-17-3 60201 InChiKey: QASFUMOKHFSJGL-LAFRSMQTSA-N

InChiKey: QASFUMOKHFSJGL-LAFRSMQTSA-N

reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease

Activation of human FFA4 by TUG-891 also results in rapid phosphorylation and internalization of the receptor

is an activator of Akt that blocks its membrane translocation while allowing its phosphorylation

and 100 mg/kg

TraMetinib - CAS# 871700-17-3 60201 InChiKey: QASFUMOKHFSJGL-LAFRSMQTSA-NTrametinib, also known as GSK1120212, CAS No. 871700 17 3, is a n orally bioavailable inhibitor of mitogen activated protein kinase kinase (MEK MAPK ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine tyrosine kinases often upregulated in